Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphate Buffered Saline (PBS) is a sterile, physiological salt solution used as a placebo control in clinical trials, specifically within Vical's development program for pandemic influenza DNA vaccines. In the Phase 1 study (NCT00471133), PBS was administered via intramuscular injection using the Biojector 2000 needle-free system to healthy volunteers. It serves as a pharmacologically inert comparator to evaluate the safety and immunogenicity of active investigational products such as VCL-IPM1 and VCL-IPT1. The solution typically contains sodium chloride and phosphate salts to maintain a stable pH and osmotic pressure consistent with human biological fluids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphate buffered saline.